Meridiano

Add Article

No Image Available

Article Details

Title

Article: FDA contradicts Trump admin, declines to approve generic drug for autism

Impact Score

5 / 10

AI Summary (Processed Content)

In September, Trump administration officials, including FDA Commissioner Marty Makary, made bold public claims promoting the drug leucovorin as a promising treatment for autism. This promotion led to a 71% increase in new outpatient prescriptions of the drug for children and adolescents in the following three months.

However, the FDA has now officially approved leucovorin only for a rare genetic condition called cerebral folate deficiency in adults, not for autism. Senior FDA officials stated they found little evidence to support the drug's use for autism, contradicting the earlier administration claims.

The main topics covered are the promotion of a drug for autism by administration officials, the subsequent spike in prescriptions, and the FDA's official rejection of that use in favor of a narrow approval for a rare genetic condition.

Original URL

https://arstechnica.com/health/2026/03/fda-contradicts-trump-admin-declines-to-approve-generic-drug-for-autism/

Source Feed

Ars Technica

Published Date

2026-03-10 22:12

Fetched Date

2026-03-10 19:30

Processed Date

2026-03-10 19:31

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

In September, the Trump administration took what it called “bold actions” on autism that included touting the generic drug leucovorin as a promising treatment. In a news release, Marty Makary, commissioner of the Food and Drug Administration, claimed a “growing body of evidence suggests” the drug could be helpful. And at a White House press event, Makary suggested it might help “20, 40, 50 percent of kids with autism.”
“Hundreds of thousands of kids, in my opinion, will benefit,” he said at another point in the event.
The bold claims were apparently persuasive. A study published in The Lancet last week found that new outpatient prescriptions of leucovorin for children ages 5 to 17 shot up 71 percent in the three months after the Trump administration’s actions.
But it became clear today that the rest of the FDA did not share Makary’s and the other administration officials’ view. In an announcement, the regulatory agency said it had approved leucovorin for a rare genetic condition—but not for autism.
In comments to the Associated Press, senior FDA officials said they found little evidence for expanding the drug’s use to autism and, thus, narrowed its review to the treatment of the rare genetic condition, which is cerebral folate deficiency (CFD) in adults caused by a genetic mutation in the folate receptor 1 gene (CFD-FOLR1).